Reporting Quality of Evaluations of Additional Risk Minimisation Measures by MAH: An Assessment of Studies Submitted in the European Union

被引：0
|
作者：
Okai, J. [1 ,2 ]
Bahri, P. [2 ]
Sarinic, V. Macolic [2 ]
机构：
[1] Univ Utrecht, Pharmaceut Sci, Utrecht, Netherlands
[2] European Med Agcy, Human Med Div, Pharmacovigilance Off, Amsterdam, Netherlands
来源：
DRUG SAFETY | 2021年 / 44卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
P003
引用
收藏
页码：1402 / 1403
页数：2
相关论文
共 28 条
  • [1] Variability in Reporting Participation Data in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union
    Artime, Esther
    Vora, Pareen
    Asiimwe, Alex
    Soriano-Gabarro, Montse
    Qizilbash, Nawab
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 425 - 425
  • [2] Assessment of colobreathe risk minimisation measures in the European Union: a cross-sectional study
    Kaplan, Sigal
    Patino, Oliver
    Rainville, Carolyn
    Madison, Terri
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 464 - 464
  • [3] Additional risk minimisation measures in the EU- are they eligible for assessment?
    Zomerdijk, Inge M.
    Trifiro, Gianluca
    Sayed-Tabatabaei, Fakhredin A.
    Sturkenboom, Miriam C. J. M.
    Straus, Sabine M. J. M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 (10) : 1046 - 1053
  • [4] Impact of the 2012 European Pharmacovigilance Legislation on Required Additional Risk Minimisation Measures
    Francisca, R. D. C.
    Zomerdijk, I. M.
    Sturkenboom, M. C. J. M.
    Straus, S. M. J. M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 415 - 415
  • [5] Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder
    Agyemang E.
    Bailey L.
    Talbot J.
    Pharmaceutical Medicine, 2017, 31 (2) : 101 - 112
  • [6] Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
    Hina Patel
    Thanh G. N. Ton
    Jessica Davies
    Simon Fear
    Carolin Block
    Kunihiko Tanaka
    Danny Gonzalez
    Roger Mutter
    Noelia Alfaro-Oliver
    Ignacio Mendez
    Nawab Qizilbash
    Pharmaceutical Medicine, 2021, 35 : 339 - 351
  • [7] Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
    Patel, Hina
    Ton, Thanh G. N.
    Davies, Jessica
    Fear, Simon
    Block, Carolin
    Tanaka, Kunihiko
    Gonzalez, Danny
    Mutter, Roger
    Alfaro-Oliver, Noelia
    Mendez, Ignacio
    Qizilbash, Nawab
    PHARMACEUTICAL MEDICINE, 2021, 35 (06) : 339 - 351
  • [8] Sampling Methods Used and Country Selection in Survey Studies Evaluating the Effectiveness of Risk Minimisation Measures in the European Union
    Artime, Esther
    Vora, Pareen
    Asiimwe, Alex
    Soriano-Gabarro, Montse
    Qizilbash, Nawab
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 425 - 426
  • [9] Evaluating the Effectiveness of Additional Risk Minimisation Measures (aRMM) for Voriconazole in 10 European Countries
    Lem, Joanna
    Younus, Muhammad
    Aram, Jalal
    Moosavi, Shahrzad
    Freivogel, Klaus
    Lewis, Anne
    Sobel, Rachel E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 424 - 425
  • [10] Additional Risk Minimisation Measures Targeting Patients in the PRAC Era: A Qualitative Review of the European Public Assessment Report Database
    Arriegas, Madalena
    Rubino, Annalisa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 288 - 288
123